Antiretroviral therapy and women’s health.

Slides:



Advertisements
Similar presentations
Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
Advertisements

STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Section 22.4 Protecting Yourself From HIV and AIDS Objectives
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.
11 HIV and contraception – complex issues for safe choice: the latest recommendations from the World Health Organization (WHO) Mary Lyn Gaffield, Sharon.
Unit 5: IPT Isoniazid TB Preventive Therapy
HIV/AIDS Presented by Kunphen center for substance dependence and HIV/AIDS.
Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Immigration Removal Centres and HIV Clinical Care Jane Anderson Homerton University Hospital NHS Foundation Trust.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
Providing Treatment, Restoring Hope Secondary Prevention as part of HIV Clinical Care Martine Etienne, MPH, DrPH University of Maryland School of Medicine.
Predicting Pregnancy Risk among Women Attending an STD Clinic Judith Shlay MD, MSPH Denver Public Health September 21, 2008 CityMatCH Conference.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
PRECONCEPTION COUNSELING AND CARE FOR HIV-INFECTED WOMEN OF CHILDBEARING AGE.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
Claudia Velgara Psychology Period 5. An anxiety disorder in which a person is continually tense, apprehensive, and in a state of autonomic nervous system.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
OB/GYN Review Course: Women and HIV Questions Peter G. Gulick, DO, FACP, FACOI Associate Professor.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
Evaluation of effectiveness and safety of acyclovir 1gm twice a day for treatment of recurrent genital herpes Kaushal Verma, M Sunane, Somesh Gupta All.
Maternal clinical considerations
Maternal Toxicity Management
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Maternal clinical considerations
CHILDREN and HIV.
Hepatitis C.
PrEP for HIV Prevention
Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design
Comparison of INSTI vs PI
On behalf of The MTN-020/ASPIRE Study Team
Pharmacokinetics: HIV Drugs
Maternal Toxicity Management
What’s Your Health IQ? True or False
Maternal Toxicity Management
Pharmacokinetics: HIV Drugs
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
Is it a potential indicator to initiate HAART?
VL patient support: General education at different levels
New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs)  HIV positive.
Overview.
Section 22.4 Protecting Yourself From HIV and AIDS Objectives
Andrew Lofts Gray Division of Pharmacology
Section 22.4 Protecting Yourself From HIV and AIDS Objectives
Basic principles of DDIs with ARVs: an introduction
MTN-037 Protocol Overview
Adele Schwartz Benzaken
Why Dolutegravir? Daniel R. Kuritzkes, M.D.
Comparison of INSTI vs EFV
Comparison of NNRTI vs NNRTI
Comparison of NNRTI vs NNRTI
Switch to ATV/r monotherapy
ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.
Diagnosis and Management of HIV-2 in Adults
Farinaz khan Dept of FCM
Dolutegravir in PEPFAR
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Public Health Implications
Presentation transcript:

Antiretroviral therapy and women’s health. Dr. Claudia Cortés M. Associate professor Universidad de Chile ccortes@fundacionarriaran.cl

Are women really different from men?

YES…. In so many many ways… Just from the HIV perspective: Pathogenesis HIV reservoir PK-PD Participation in trials Social Factors

Barriers to a cure for HIV in women Gianella S et al. J Int AIDS Soc. 2016; 19(1): 20706

Sex Differences Relating to HIV Treatment and Disease Progresssion. Female sex is associated with: Lower HIV viral load (JAIDS 2002;31:11-19) Higher CD4+ count (AIDS 1997;11:1071-3) More pronounced immune and vaccine responses (JAIDS 2011;57:9-15) Higher levels of immune activation (JID 2013;208:830-8) More frequent ART side effects and discontinuation (J Antimicrob Chem 2007; 60: 724-32)

Conclusions Women and men potentially differ in the course of their HIV infection, their response to treatment and drug pharmacokinetics, all of which are compounded by social and behavioral factors Conclusions Gender inequalities in the response to cART are mainly explained by the different prevalence of socioeconomic characteristics in women compared with men. Conclusions It is essential to understand sex differences in drug response, as they may affect drug safety and effectiveness.

Sex Difference Considerations in ART In general, studies have not shown sex differences in virologic responses to ART. There are limited data showing that pharmacokinetics for some ARV drugs may differ between men and women, possibly because of variations in factors such as: Gender differences in the treatment of HIV infection. Pharmacological Research 58 (2008) 173–182

Clinical Case Camila, 26 years of age A journalist Recently diagnosed after blood donation After extensive counseling baseline lab test are done:

Lab tests: HBsAg negative Total anti-HBc negative HCV negative RPR (1/8) TST negative HIV Viral load 83,000 cps/mL CD4 385 cels/mm3 Normal physical examination Medication: Levothyroxine 50 mcgr Nuvaring (etonogestrel/ethinyl estradiol) Multivitamins Habits: Vegetarian Marihuana once or twice a month Ecstasy (twice in her life) Currently single

Discuss childbearing intentions with all women of childbearing age and reassess frequently Preconception care Prevention of unintended pregnancies Evaluation of effective and appropriate contraceptive methods Optimization of women health (prior pregnancy/or not) Include information on safe sex, restriction of alcohol, illicit drugs and smoking Prevention of HIV transmission to an uninfected partner Prevention and treatment of other STDs What general considerations are important with this patient of childbearing age?

What are the main considerations in relation to ART in Camila? Choice of individualized ART, considering: Previous history of ART Known resistance patterns Adverse effects and toxicities Optimize adherence Probable effects on a possible fetus-newborn What are the main considerations in relation to ART in Camila? In agreement with the patient: FTC/TDF + DTG was prescribed

Monday 22 July 14:30-16:00 Sala A

Camila wants to be sure that the vaginal ring is effective. Is it? What are the interactions we need to be aware of?

EFV based ART decreased EE by 53-57% and ENG by 76-79% EFV based ART may decrease the effectiveness of vaginal ring contraceptive ATV/r based ART decreased EE concentration 29-35%, but increased ENG concentrations by 71-79% ATV/r based ART is unlikely to impact the effectiveness of vaginal ring contraceptives

Camila wants to be sure that the vaginal ring is effective. Is it?

emergency contraception Be careful with emergency contraception Infect Dis Obstet Gynecol 2012 ID137192

What about Camila´s use of recreational drugs?

Should she be? Should she be? After a few months Camila complains of sleeping difficulties and emotional instability She was evaluated by a mental health unit: adaptive disorder and first episode of depression She is concerned about the role of the ARV in this depression diagnosis Should she be? Should she be?

Depression & HIV Depression is the most common neuropsychiatric complication in HIV-infected patients and may occur in all phases of the infection Compared to the general population and comparable HIV seronegative subjects, the prevalence of clinical depression is two- to fourfold higher in HIV + individuals As in the general population, gender is considered a risk factor for depression, with females being at increased risk Curr Psychiatry Rep (2015) 17:530

Conclusions: Analysis of 3 different data sources shows that, similar to other frequently prescribed anchor, psychiatric symptoms are also reported in DTG-treated patients. These events are reported with low frequency and rarely necessitate DTG discontinuation J Acquir Immune Defic Syndr 2017; 74: 423-431 Curr Opin HIV AIDS 2018; 13: 102-111

What about Camila’s Multivitamins Multivitamins often contain divalent cations such as calcium, magnesium and Iron. All the integrase inhibitors are affected by cation containing preparations – including multivitamins, calcium supplements and antacids

What about Camila’s multivitamins? Mean plasma concentration-time profiles of DTG (50 mg, single dose) with and without calcium carbonate (CC) (1,200 mg, single dose). Song I et al J Clin Pharmacol. 2015 May; 55(5): 490–496.

Current Recommendations in SmPC for Integrase Inhibitors and Ca++ containing preparations Cation Raltegravir Dolutegravir Elvitegravir/c Bictegravir Calcium containing No dose adjustment (bd) Not recommended (qd) Separate well (DTG 2h before or 6h after) Ca++ Not specifically stated Separate by at least 4h for Al++/Mg++ Can be taken together without regard to food*. Mg2+ Mg2+ * Food reduces the impact of the cation on exposure (by ~ 30%). Genvoya SmPC 04/19; Tivicay SmPc 04/19.; Isentress SmPC 03/19; Biktarvy SmPC 11/18

Don’t forget about “natural” medications and herbs

Results: Women represent a median of: 19.2% participants in ART studies 38.1% participants in vaccine studies 11.1% in cure studies